What is this medication?
Anti-Parkinson Agent; Dopamine Agonist
Officially indicated for treatment of parkinson disease, restless leg syndrome (immediate release only).
How does this medication work?
Ropinirole, Requip is a non-ergot dopamine agonist that binds to dopamine receptors and has dopaminergic activity on the nerves of the striatum and substantia nigra.
How should I take this medication?
Oral Immediate Release: 0.25mg three times per day then titrate up to a maximum of 24mg/day divided for Parkinson (0.25mg once daily up to 4mg daily for RLS)
Oral Extended Release: 2mg to 24mg once daily.
How to Take: Take with or without food. Swallow the extended release tablets whole; do not crush, chew, or divide. For restless legs syndrome, administer 2 to 3 hours before bedtime; if augmentation occurs, dose earlier in the day, divide into multiple daily doses, or consider switching to alternative therapy.
What should I watch for while using this medication?
Before starting Ropinirole, Requip make sure your physician is aware of any allergies or medications you currently take. You may experience dyskinesias, loss of impulse control, neuroleptic malignant syndrome and orthostatic hypotension, increased melanoma risk, retinal changes, psychotic effects, and severe somnolence while taking Ropinirole, Requip.
What if I miss a dose?
If you miss a dose of medication, try to take it as soon as possible. However, if it is almost time for your next dose, take only that scheduled dose. Do not take double or extra doses.
How should I store this medication?
Keep out of the reach of children at all times. Store at room temperature, 59 to 86° F (15 to 30° C). Protect from light. Keep the container tightly closed. Properly dispose of any unused medication after the expiration date.
What are the possible side effects of using this medication?
Cardiovascular: Hypotension (RLS: ≤25%; PD: 2%), orthostatic hypotension (RLS: ≤25%; PD: 6%; extended release: 14%), hypertension (PD: 5%; extended release: 3% to 15%), syncope (PD: ≤12%; RLS: 1% to 2%; sometimes associated with bradycardia)
Central nervous system: Drowsiness (PD: ≤40%; extended release: 8% to 15%; RLS: 12%), dizziness (PD: 40%; extended release: 6% to 10%; RLS: 11%), headache (PD, extended release: 5% to 15%)
Gastrointestinal: Nausea (PD: 60%; RLS: 40%; extended release: 10% to 33%), vomiting (PD: 12%; extended release: 10%; RLS: 11%)
Infection: Viral infection (PD: 11%)
Neuromuscular & skeletal: Asthenia (PD: 16%; RLS: 9%), back pain (PD, extended release: 5% to 15%)
- Choosing a selection results in a full page refresh.
- Press the space key then arrow keys to make a selection.